HRS 4357
Alternative Names: HRS-4357Latest Information Update: 28 Nov 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 30 Sep 2023 Phase-I/II clinical trials in Prostate cancer (Late-stage disease) (Parenteral) (NCT06006104)
- 28 Aug 2023 Preclinical trials in Prostate cancer in China (Parenteral), prior to August 2023 (Jiangsu HengRui Medicine pipeline, August 2023)
- 16 Aug 2023 Jiangsu HengRui Medicine Co. plans a phase I/II trial in Prostate Cancer (Late-stage disease) in China (Parenteral, Injection) (NCT06006104)